The Indian pharmaceutical market recorded 13.5% growth in September 2026, hitting a three-year high driven by chronic therapies. While Nomura retains a positive view on domestic leaders, investors are tracking potential earnings pressure from a proposed 30% trade margin cap on anti-scheduled anti-cancer drugs. Additionally, USFDA inspections remain a key focus for companies like Dr. Reddy’s.
The Indian pharmaceutical market (IPM) has recorded a 13.5% year-on-year growth in September 2026, marking its strongest performance in three years. This growth is largely driven by a 3.5% increase in volume, the highest seen in two years, alongside price hikes in established product segments. Brokerage firm Nomura has maintained a positive outlook on the sector, citing the strength of domestic players with robust specialty portfolios.
Chronic Therapies Drive Demand
The expansion is primarily supported by consistent demand in chronic therapy segments, which require long-term treatment. Categories including cardiology, diabetes, and neuro-CNS treatments have provided a stable foundation for revenue growth. In particular, the oncology segment has outperformed, showing growth of more than 20% compared to the same period last year. Companies such as Sun Pharmaceutical Industries and Zydus Lifesciences were notable growth performers, benefiting from their diversified product mix and high-margin specialty offerings.
Regulatory and Operational Headwinds
While the sector is seeing strong demand, investors are closely monitoring potential risks that could impact future earnings. The Indian government is reportedly planning to cap trade margins at 30% of the maximum retail price (MRP) for 110 non-scheduled anti-cancer drugs, with implementation expected later in October 2026. This move is intended to reduce medicine costs for patients but could put pressure on the profit margins of companies with large portfolios in this specific segment.
Beyond government policy, operational quality remains a critical factor. Dr. Reddy’s Laboratories recently received a Form 483 from the US Food and Drug Administration (USFDA) with two observations following an inspection of its FTO-11 manufacturing facility in Andhra Pradesh from October 5–7, 2026. Such regulatory observations often require companies to take corrective actions, and while not unusual in the industry, they can lead to delays in product approvals or additional compliance spending.
What Investors Should Monitor
Moving forward, the primary areas of focus for the sector will be the final notification regarding the trade margin caps and how individual companies manage their manufacturing compliance. Furthermore, while the current domestic demand remains strong, global factors like currency fluctuations and generic pricing pressures in international markets continue to be variables that impact the overall profitability of Indian pharmaceutical firms. Investors may track future quarterly results to see if the recent volume growth translates into sustained improvement in cash flow and return ratios.